See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Ford Motor Company (F) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ford Motor Company (F) - free report >>
Tesla Shares Can't Stop & Won't Stop
Tesla (TSLA - Free Report) is up 75% so far this year, appearing to defy logic. The global pandemic has hammered the broader automotive industry but leaving Tesla relatively unscathed. Ford (F - Free Report) , Fiat , and GM (GM - Free Report) are suffering from significant supply chain issues and a demand halt.
Demand for Tesla vehicles remains strong amid the global pandemic. In Q1, Tesla was able to produce 100,000 vehicles and delivered 88,400. These figures were substantially above expectations and added fuel to TLSA’s recent rally.
The Shanghai Gigafactory is operating ahead of expectations. Tesla vehicle registration in China jumped 450% between February and March.
Its direct-to-consumer business model gives the company more flexibility amid this pandemic. Tesla is shifting the automotive world to an industry driven by technology. TSLA is well on its way to becoming the largest publicly traded automaker (by market cap) with only one more company to pass: Toyota (TM).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>